Yttrium-90 Radioembolization for Liver Malignancies: Prognostic Factors Associated with Survival

Journal of Vascular and Interventional Radiology

Volumn 21, Issue 1, 2010, Pages 90-95

  Dunfee, Brian L ^a   Riaz, Ahsun ^b   Lewandowski, Robert J ^b   Ibrahim, Saad ^b   Mulcahy, Mary F ^b   Ryu, Robert K ^b   Atassi, Bassel ^b   Sato, Kent T ^b   Newman, Steven ^b   Omary, Reed A ^b   Benson III, Al ^b   Salem, Riad ^b  

^a DII Diagnostic Imaging Inc   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LIVER CANCER; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR VOLUME;

AGED; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; ILLINOIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 72549112436     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2009.09.011     Document Type: Article

References (27)

1. Rougier P., Milan C., Lazorthes F., et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 82 (1995) 1397-1400
2. Chang A.E., Steinberg S.M., Culnane M., and White D.E. Determinants of survival in patients with unresectable colorectal liver metastases. J Surg Oncol 40 (1989) 245-251
3. Kemeny N., Niedzwiecki D., Shurgot B., and Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer 63 (1989) 742-747
4. Yuste A.L., Aparicio J., Segura A., et al. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2 (2003) 231-234
5. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5 (1982) 649-655
6. Allen P.J., Kemeny N., Jarnagin W., DeMatteo R., Blumgart L., and Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7 (2003) 109-115
7. 90Y microspheres-safety, efficacy, and survival. Radiology 247 (2008) 507-515
8. Gray B.N., Burton M.A., Kelleher D.K., Anderson J., and Klemp P. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. J Surg Oncol 42 (1989) 192-196
9. Salem R., and Thurston K.G. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17 (2006) 1251-1278
10. Meade V.M., Burton M.A., Gray B.N., and Self G.W. Distribution of different sized microspheres in experimental hepatic tumours. Eur J Cancer Clin Oncol 23 (1987) 37-41
11. Rhodes S. Humanitarian device exemptions (HDE) regulations: questions and answers; final guidance for industry. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/ guidancedocuments/ucm071474.pdf Accessed August 10, 2009
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92 (2000) 205-216
13. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48 (1979), WHO, Geneva
14. Carr B.I. Hepatic arterial 90Yttrium glass microspheres (TheraSphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10 suppl (2004) S107-S110
15. Cox D.R., and Oaks D. Analysis of survival data (1984), Chapman & Hall, London
16. Goin J.E., Salem R., Carr B.I., et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16 (2005) 205-213
17. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16 (2005) 1627-1639
18. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
19. Lewandowski R.J., Thurston K.G., Goin J.E., et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16 (2005) 1641-1651
20. Herba M.J., and Thirlwell M.P. Radioembolization for hepatic metastases. Semin Oncol 29 (2002) 152-159
21. Gray B.N., Anderson J.E., Burton M.A., et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg 62 (1992) 105-110
22. Scheele J., Stang R., Altendorf-Hofmann A., and Paul M. Resection of colorectal liver metastases. World J Surg 19 (1995) 59-71
23. Doci R., Gennari L., Bignami P., Montalto F., Morabito A., and Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 78 (1991) 797-801
24. Lewandowski R.J., Kulik L.M., Riaz A., et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9 (2009) 1920-1928
25. Johnson K.R., Ringland C., Stokes B.J., et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7 (2006) 741-746
26. Sarmiento J.M., Heywood G., Rubin J., Ilstrup D.M., Nagorney D.M., and Que F.G. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197 (2003) 29-37
27. Chamberlain R.S., Canes D., Brown K.T., et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg 190 (2000) 432-445